FCGR2A and neoplasm: Based on these results, studies on human patients receiving tumor antigen-specific IgG antibodies have shown that treatment outcomes could be improved if patients carried engineered antibodies against alleles of human FcγR with a higher affinity for the therapeutic antibody [47,48,49].